These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 33246983)

  • 1. Cost-effectiveness of new antiviral treatments for non-genotype 1 hepatitis C virus infection in China: a societal perspective.
    Wei X; Zhao J; Yang L
    BMJ Glob Health; 2020 Nov; 5(11):. PubMed ID: 33246983
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-Effectiveness Analysis of Pan-Genotypic Sofosbuvir-Based Regimens for Treatment of Chronic Hepatitis C Genotype 1 Infection in China.
    Zhou HJ; Cao J; Shi H; Naidoo N; Semba S; Wang P; Fan YF; Zhu SC
    Front Public Health; 2021; 9():779215. PubMed ID: 34957030
    [No Abstract]   [Full Text] [Related]  

  • 3. Cost-utility of sofosbuvir/velpatasvir versus other direct-acting antivirals for chronic hepatitis C genotype 1b infection in China.
    Yun H; Zhao G; Sun X; Shi L
    BMJ Open; 2020 Aug; 10(8):e035224. PubMed ID: 32819983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of daclatasvir plus sofosbuvir-based regimen for treatment of hepatitis C virus genotype 3 infection in Canada.
    Moshyk A; Martel MJ; Tahami Monfared AA; Goeree R
    J Med Econ; 2016; 19(2):181-92. PubMed ID: 26453248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world cost-effectiveness of pan-genotypic Sofosbuvir-Velpatasvir combination versus genotype dependent directly acting anti-viral drugs for treatment of hepatitis C patients in the universal coverage scheme of Punjab state in India.
    Chugh Y; Dhiman RK; Premkumar M; Prinja S; Singh Grover G; Bahuguna P
    PLoS One; 2019; 14(8):e0221769. PubMed ID: 31465503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-Effectiveness Analysis of Oral Direct-Acting Antivirals for Chinese Patients with Chronic Hepatitis C.
    Chen P; Jin M; Cao Y; Li H
    Appl Health Econ Health Policy; 2021 May; 19(3):371-387. PubMed ID: 33210262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic evaluation of pan-genotypic generic direct-acting antiviral regimens for treatment of chronic hepatitis C in Iran: a cost-effectiveness study.
    Tasavon Gholamhoseini M; Sharafi H; Hl Borba H; Alavian SM; Sabermahani A; Hajarizadeh B
    BMJ Open; 2022 Jun; 12(6):e058757. PubMed ID: 35676019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis of the use of daclatasvir + sofosbuvir + ribavirin (16 weeks and 12 weeks) vs sofosbuvir + ribavirin (16 weeks and 24 weeks) for the treatment of cirrhotic patients affected with hepatitis C virus genotype 3 in Italy.
    Restelli U; Alberti A; Lazzarin A; Bonfanti M; Nappi C; Croce D
    Eur J Health Econ; 2018 Jan; 19(1):37-44. PubMed ID: 28008546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness analysis of glecaprevir/pibrentasvir regimen for treating Chinese patients with chronic hepatitis C genotype 1 and genotype 2 infection.
    Zhou HJ; Wu G; Li JM; Naidoo N; Xie YX; Feng BL; Wang P; Luo JW
    Ann Palliat Med; 2021 Oct; 10(10):10313-10326. PubMed ID: 34670381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world effectiveness of daclatasvir plus sofosbuvir and velpatasvir/sofosbuvir in hepatitis C genotype 2 and 3.
    Belperio PS; Shahoumian TA; Loomis TP; Mole LA; Backus LI
    J Hepatol; 2019 Jan; 70(1):15-23. PubMed ID: 30266283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-Effectiveness Modelling of Sofosbuvir-Containing Regimens for Chronic Genotype 5 Hepatitis C Virus Infection in South Africa.
    Fraser I; Burger J; Lubbe M; Dranitsaris G; Sonderup M; Stander T
    Pharmacoeconomics; 2016 Apr; 34(4):403-17. PubMed ID: 26666639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-Effectiveness Analysis of New HCV Treatments in Egyptian Cirrhotic and Non-Cirrhotic Patients: A Societal Perspective.
    Elsisi GH; Aburawash A; Waked E
    Value Health Reg Issues; 2017 Sep; 13():7-15. PubMed ID: 29073993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of generic pan-genotypic sofosbuvir/velpatasvir versus genotype-dependent direct-acting antivirals for hepatitis C treatment.
    Goel A; Chen Q; Chhatwal J; Aggarwal R
    J Gastroenterol Hepatol; 2018 Dec; 33(12):2029-2036. PubMed ID: 29864213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis of Daclatasvir/Sofosbuvir for the treatment of the HCV patients failed after the first line with second generation of DAAs in Italy.
    Ruggeri M; Rolli FR; Kondili LA; Drago C; De Solda F; Nappi C; Cicchetti A
    Expert Rev Pharmacoecon Outcomes Res; 2019 Jun; 19(3):363-374. PubMed ID: 30351994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of combination daclatasvir-sofosbuvir for treatment of genotype 3 chronic hepatitis C infection in the United States.
    Saint-Laurent Thibault C; Moorjaney D; Ganz ML; Sill B; Hede S; Yuan Y; Gorsh B
    J Med Econ; 2017 Jul; 20(7):692-702. PubMed ID: 28294645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-utility analysis of four WHO-recommended sofosbuvir-based regimens for the treatment of chronic hepatitis C in sub-Saharan Africa.
    Boyer S; Baudoin M; Nishimwe ML; Santos M; Lemoine M; Maradan G; Sylla B; Kouanfack C; Carrieri P; Mourad A; Rouveau N; Moh R; Seydi M; Attia A; Woode ME; Lacombe K
    BMC Health Serv Res; 2022 Mar; 22(1):303. PubMed ID: 35248039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-utility analysis of ledipasvir/sofosbuvir for the treatment of genotype 1 chronic hepatitis C in Japan.
    Igarashi A; Tang W; Guerra I; Marié L; Cure S; Lopresti M
    Curr Med Res Opin; 2017 Jan; 33(1):11-21. PubMed ID: 27609424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of novel regimens for the treatment of hepatitis C virus.
    Najafzadeh M; Andersson K; Shrank WH; Krumme AA; Matlin OS; Brennan T; Avorn J; Choudhry NK
    Ann Intern Med; 2015 Mar; 162(6):407-19. PubMed ID: 25775313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of sofosbuvir plus ribavirin therapy for hepatitis C virus genotype 2 infection in South Korea.
    Chung W; Kim KA; Jang ES; Ki M; Choi HY; Jeong SH
    J Gastroenterol Hepatol; 2019 Apr; 34(4):776-783. PubMed ID: 30462841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness analysis of sofosbuvir and velpatasvir in chronic hepatitis C patients with decompensated cirrhosis.
    Chan J; Kim JJ; Barrett BK; Hamadeh A; Feld JJ; Wong WWL
    J Viral Hepat; 2021 Feb; 28(2):260-267. PubMed ID: 33065774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.